Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in systemic lupus erythematosus (SLE), which affects around 3.4 million people ...

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Kennedy suggested the requirement for CES is one reason why the US is lagging behind other parts of the world in the rollout ...

Shares in Novartis had fallen nearly 3.5% at the time of writing, as investors digested the third-quarter figures and ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...